Abstract:The increasing prevalence of multiple-antibiotic resistant bacteria is a major public health problem. Recent summits have been held by the New South Wales and Victorian governments to develop strategies to combat this threat within the public hospital system. Papers in this issue of Pathology remind us, however, that the problem with multiple-antibiotic resistant bacteria is not confined to hospitals. The increasing importance of communityacquired methicillin-resistant Staphylococcus aureus (MRSA) and an apparent increase in serious infection due to such strains is highlighted. The emergence of methicillin resistance in S. aureus isolates recovered from non-hospitalised patients (community MRSA) is a worldwide phenomenon. Unlike typical hospital strains of MRSA, community strains are often non-multiresistant (defined as resistant to (3 non-blactam antibiotics). Following their first appearance among intravenous drug users in the late 1980s, epidemics of community MRSA have moved beyond the original demographic groups. In Australia, such isolates first appeared in Western Australia in the early 1990s, initially in patients from remote areas of the Kimberly and Gold Fields regions, but soon became the predominant ‘type’ of MRSA strains in Perth, with subsequent spread to the eastern states in the late 1990s. Here, isolates were initially recovered from Polynesian visitors or migrants, with molecular typing studies confirming that these strains were identical to those responsible for epidemics in New Zealand and the Pacific Islands. Today, community MRSA strains have been seen in all ethnic groups, particularly in Sydney and Brisbane, and have been increasingly recovered from patients in rural communities and in the indigenous population. Importantly, strains of MRSA have also been introduced into Australia from further afield. In particular, epidemic MRSA (EMRSA)-15 and EMRSA-16 strains from the United Kingdom are increasingly reported in Australia, probably introduced by British healthcare workers. If the British experience is anything to go by, this is of particular concern, as these initially community strains appear to be persistent colonisers and spread readily once introduced into nursing homes and hospitals; they have become the predominant MRSA strains in UK hospitals within only a few years. The paper by Gosbell and co-workers highlights the complexity in epidemiology of MRSA in Australia, which becomes readily apparent when isolates are genotyped using methods such as multilocus sequencing. Interestingly, there was a diverse range of genotypes: of 16 patients with community MRSA bacteraemia in western Sydney, half were infected with a nosocomial strain (the UK EMRSA15 strain), only three were infected with an Oceania strain, and the remaining with Western Australian or Queensland strains. Most of the patients had risk factors for infection. Unfortunately the Staphylococcal Reference Facility at Liverpool Hospital has now had its government funding withdrawn, severely compromising the ability of researchers in eastern Australia to conduct such studies in the future. Community strains of MRSA possess the mecA gene complex and hence are resistant to all currently available blactam agents. Whilst typically susceptible to other drug classes such as the aminoglycosides, macrolides, tetracyclines, sulphonamides and quinolones (EMRSA-15 strains are quinolone resistant), resistance to these agents may be readily acquired, so that laboratory testing is essential to guide therapy. However, there is no standardisation of which non-b-lactams should be incorporated into antimicrobial testing algorithms for these organisms, and data regarding the relative therapeutic efficacy of these agents for treating the spectrum of infections caused by community MRSA are incomplete. Gosbell presents the results of time-kill and disc synergy studies on an Oceania phage type strain, and recommends that clindamycin, cotrimoxazole or doxycycline could be used for treatment of mild to moderate infections such as boils and cellulitis. Certainly, clindamycin has become the treatment of choice for such community MRSA infections in many centres. The study by Pimentel and Lum is a useful reminder for laboratories to be vigilant in detecting inducible clindamycin resistance (ICR) in S. aureus strains, which appear resistant to erythromycin but susceptible to clindamycin (i.e., dissociative resistance). In their evaluation of the ‘D-test’, ICR was recognised in all 100 isolates with dissociative macrolide and lincosamide resistance. Vancomycin remains the mainstay of therapy for bacteraemia and other serious invasive infections with MRSA, whether community or hospital acquired. Increasing reports of MRSA with reduced susceptibility to vancomycin (so-called ‘VISA’ strains) in Australia, including in non-multiresistant strains, underscores the need for accurate and timely determination of antimicrobial susceptibility by laboratories. Whilst most commonly cause skin and soft tissue infections, community MRSA are increasingly responsible for serious life-threatening invasive infections. Multiple Pathology (June 2006) 38(3), pp. 199–200

Increased Serum Amyloid A As Potential Diagnostic Marker for Lung Cancer: a Meta-Analysis Based on Nine Studies

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma.

Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Serum amyloid A for predicting prognosis in patients with newly diagnosed Crohn's disease

Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma

High SAA1 Expression Predicts Advanced Tumors in Renal Cancer

Diagnostic Value of Serum 7-AABs Combined with CEA and CA199 in the Detection of Lung Cancer

Serum amyloid A-low-density-lipoprotein complex and cause-specific mortality in patients with suspected or known coronary artery disease: The ANOX Study

Combination of Serum Amyloid A and C-Reactive Protein Exhibit Synergistic Effect in Angiogenesis by Inducing Inflammation and Vascular Network

Clinical Value of Seven Autoantibodies Against Tumor-Associated Antigens and Tumor Markers in Lung Cancer Patients: A Retrospective Analysis from a Single Institution

Association between Serum Amyloid A Levels and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?

SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma

Protein Glycopatterns in Bronchoalveolar Lavage Fluid as Novel Potential Biomarkers for Diagnosis of Lung Cancer

The effect and mechanism of murine serum amyloid A 1,2,3,4 on metastasis of Lewis lung carcinoma cell lines

The effect of murine serum amyloid A on tumor metastasis

Cytokine Signatures for Lung Cancer Diagnosis in African American Populations

Serum amyloid A levels in patients with liver diseases.

Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules

Meta-analysis of the accuracy for RASSF1A methylation in bronchial aspirates for the diagnosis of lung cancer

Community-acquired methicillin-resistant Staphylococcus aureus: time for action.